Nordea Investment Management AB Invests $4.07 Million in TransMedics Group, Inc. $TMDX

Nordea Investment Management AB acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 36,372 shares of the company’s stock, valued at approximately $4,070,000. Nordea Investment Management AB owned 0.11% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC purchased a new position in TransMedics Group in the 2nd quarter valued at approximately $26,000. Salomon & Ludwin LLC purchased a new position in TransMedics Group in the third quarter valued at $28,000. First Horizon Corp acquired a new position in TransMedics Group during the 3rd quarter worth $43,000. Sound Income Strategies LLC purchased a new stake in TransMedics Group during the 2nd quarter worth about $48,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of TransMedics Group in the 2nd quarter valued at about $48,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the topic of several analyst reports. Needham & Company LLC raised their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research note on Monday, October 13th. They set a “buy” rating and a $145.00 target price for the company. Morgan Stanley lifted their price target on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Trading Down 0.2%

TMDX opened at $143.37 on Monday. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $156.00. The business’s 50 day moving average is $130.87 and its two-hundred day moving average is $122.55. The firm has a market cap of $4.90 billion, a price-to-earnings ratio of 58.04 and a beta of 2.03.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period last year, the firm posted $0.12 earnings per share. On average, research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling

In other news, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the transaction, the director owned 2,866 shares in the company, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 13,062 shares of company stock valued at $1,797,634 in the last quarter. 7.00% of the stock is currently owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.